Harrow, Inc. HROW

Harrow (HROW) shows strong product momentum but faces a steep H2 revenue target. Product momentum offers upside while steep H2 revenue targets introduce execution risk that may limit near-term gains.

Harrow announces IHEEZO data on patient-reported discomfort following intravitreal injections. IHEEZO data release may support product adoption and moderately affect market positioning.

Harrow (HROW) released its Q2 2026 earnings call transcript covering financial results and outlook. Earnings call transcript delivers key financial metrics and guidance that can significantly shift investor sentiment and company trajectory.

Viatris is selling Tyrvaya, opening a potential opportunity for Harrow to acquire the product and convert it into a major growth driver. Potential acquisition of Tyrvaya represents a major strategic move that could significantly expand Harrow's portfolio and alter its growth trajectory.

Harrow, Inc. launched a new eye care product and completed an acquisition to expand its portfolio and market presence in ophthalmology. Product launch combined with acquisition strengthens core operations and competitive positioning in eye care.

Harrow Inc reported record demand and outlined strategic expansion initiatives during its Q2 2026 earnings call. Record demand and strategic expansion signal major positive shifts likely to boost Harrow's growth trajectory and investor outlook.

Harrow Health, Inc. Q2 2026 earnings call outlines revenue growth, operational updates, and forward guidance for its pharmaceutical products. Q2 2026 earnings call delivers financial metrics and strategy updates that shift investor sentiment and valuation.

Harrow, Inc. (HROW) reported Q2 financial results and operational updates during its earnings call. Q2 earnings provide moderate insights into financial performance without signaling major strategic shifts.

Harrow, Inc. announced its second quarter 2026 financial results. Quarterly earnings releases typically produce moderate effects on near-term stock price and sentiment.

Harrow acquires global rights to TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease. Acquisition adds approved dry eye product with global rights to Harrow portfolio and boosts revenue outlook.

Samsung Bioepis and Harrow presented interim data from a large-scale post-marketing surveillance study on SB11 (BYOOVIZ® / AMELIVU®), a biosimilar to Lucentis (ranibizumab), at ASRS 2026. Interim surveillance data on Harrow's key biosimilar product may moderately shift market views of its ophthalmology portfolio.

Harrow highlights expanding clinical evidence for IHEEZO and BYOOVIZ at the ASRS 2026 Annual Meeting. Conference data presentations can boost product credibility and near-term market sentiment for IHEEZO and BYOOVIZ.

Harrow, Inc. launches BYOOVIZ® commercially in the United States. Commercial launch of new product expands revenue streams and competitive positioning for Harrow.

Samsung Bioepis relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in partnership with Harrow. Partnership to relaunch BYOOVIZ gives Harrow direct US commercialization rights that can drive revenue growth in ophthalmology.

Harrow relaunches VERKAZIA as part of efforts to redefine its niche ophthalmic strategy. VERKAZIA relaunch may moderately influence Harrow's product positioning and operations in ophthalmics.

Harrow Inc. relaunches ophthalmology drug Verkazia in the US, driving HROW stock higher. Verkazia US relaunch constitutes a significant product launch with direct revenue and positioning effects for Harrow.

Harrow re-launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis to address significant unmet need in pediatric eyecare. VERKAZIA re-launch targets unmet pediatric eyecare needs potentially boosting Harrow's market position and sales.

Harrow (HROW) narrative shifts as analysts recut price targets while staying positive. Analyst price target recuts with positive outlook moderately influence HROW market sentiment and trajectory.

Harrow, Inc. (NASDAQ:HROW) released first-quarter results, prompting analysts to publish new forecasts. Q1 results and analyst forecast revisions moderately impact financial performance and investor sentiment.

Harrow, Inc. (HROW) Q1 earnings call highlights key quarterly financial results, operational updates, and strategic outlook. Q1 earnings highlights detail financial performance and guidance that significantly shape investor expectations and stock trajectory.

Harrow Inc. (HROW) Q1 2026 earnings call highlights strong product demand despite revenue challenges. Strong demand boosts growth outlook while revenue hurdles temper financial performance with moderate overall impact.

Harrow Health, Inc. released Q1 2026 earnings call summary covering financial results, operational updates, and future outlook. Q1 2026 earnings call summary details financial performance and guidance with moderately noticeable influence on HROW's trajectory.

Harrow, Inc. (HROW) announced first quarter 2026 financial results. Quarterly financial results announcements typically drive significant shifts in stock price and long-term investor outlook.

Harrow, Inc. (HROW) reported a first-quarter loss and lagged revenue estimates. Q1 loss and revenue miss will noticeably impact financial performance and market sentiment.

Analysts predict Harrow (HROW) will report declining earnings, urging investors to monitor key metrics like revenue growth, expense management, and pipeline updates ahead of the earnings release. Forecasted earnings decline targets core financial performance, likely causing moderate short-term volatility in stock price and investor sentiment.

Harrow, Inc. (HROW) earns a Zacks Rank #2 (Buy) with upward earnings revisions, strong revenue growth in ophthalmology products, and favorable valuation metrics, positioning it as an attractive buy despite market volatility. Positive analyst buy rating and earnings growth signal moderate influence on financial performance and investor sentiment.

Harrow, Inc. announces the issuance of a J-Code for IOPIDINE® 1% ophthalmic solution, facilitating reimbursement and improving access for patients with elevated intraocular pressure. J-Code issuance enables Medicare reimbursement for IOPIDINE® 1%, significantly enhancing product accessibility, sales potential, and revenue for Harrow.

Harrow, Inc. (HROW) selects LogiCare3PL as its distribution partner. Partnership improves distribution operations but lacks transformative scale.

Harrow, Inc. (HROW) priced a new US$50 million senior notes offering due 2029, providing capital for general corporate purposes including potential acquisitions and growth, with mixed implications for shareholders amid higher debt levels but improved liquidity. $50 million senior notes issuance bolsters Harrow's balance sheet for strategic expansion and acquisitions, significantly influencing financial flexibility and stock performance.

Harrow, Inc. (HROW) priced a $50.0 million offering of senior unsecured notes due 2030. Pricing $50 million in senior notes provides key capital for operations and growth, significantly enhancing financial flexibility and market positioning.